Cencora (COR) earnings call transcripts

Management framed the quarter as a planned second-half acceleration, with specialty utilization and MSO execution offsetting pricing and customer pressures.

Management framed Cencora as a specialty-led, customer-centric platform entering fiscal 2025 with momentum despite COVID, GLP-1 and PharmaLex headwinds.

Management framed execution, specialty leadership and pharmaceutical trends as outweighing international softness during a planned CEO transition.

Management framed the quarter as strong execution, with customer support during the Change Healthcare disruption and CEO transition shaping the discussion.

Management framed the quarter as broad-based execution, with vaccines and GLP-1s lifting reported momentum while underlying utilization remained strong.